| Document |
Document Title |
|
WO/2024/008204A1 |
Provided is the use of MmPI in the preparation of a trypsin inhibitor. The amino acid sequence of the MmPI is as shown in SEQ ID NO. 1. In the present invention, it is confirmed that MmPI in mulberry leaves has a trypsin inhibitory activ...
|
|
WO/2024/011112A1 |
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.
|
|
WO/2024/009086A2 |
The present disclosure provides a cohort of novel viral genome derived products for use, for example, in medicine, as a medicaments, as expression vectors and as adjuvants. The disclosed viral genome derived products may be derived from ...
|
|
WO/2024/008709A1 |
Using Harlequin (Hq) mice (a model developing an ataxic phenotype), the present inventors have confirmed that neuroglobin-based gene therapy represents a very promising tool for the treatment of neurological diseases. Hq mice were subjec...
|
|
WO/2024/010119A1 |
The present invention relates to CAR-T cells that secrete EphA2 T cell engager and target EGFRvIII, which is a mutant EGFR, and according to the present invention, EGFRvIII CAR-T cells that secrete the EphA2 T cell engager exhibit specif...
|
|
WO/2024/008752A1 |
The invention relates to genetically altered plants, parts thereof or plant cells, where the plants, parts thereof or plant cells are characterised by increased levels of iron. Also described are methods of increasing the levels of iron ...
|
|
WO/2024/008959A1 |
The present invention relates to an isolated ribonucleic acid molecule to prevent and control bloom of alga.
|
|
WO/2024/008344A1 |
The invention relates to the use of an E. coli bacterial strain, for detecting in a liquid up to 50 mM, in condition of anaerobiosis, the presence, the absence or the amount of chlorate ions of formula ClO3 -, wherein said E. coli bacter...
|
|
WO/2024/010093A1 |
Provided is a chamber that can improve a fibrinogen recovery rate.　This chamber 22 accommodates plasma when the plasma is being frozen and thawed to prepare a fibrinogen liquid from the plasma. The chamber 22 comprises a film section 5...
|
|
WO/2024/011119A2 |
The present invention describes human NaV1.7 inhibitor peptides, compositions, and methods for using the peptides for treating pain.
|
|
WO/2024/008058A1 |
Provided are a GLP-1 receptor and GCG receptor co-agonist polypeptide derivative and use thereof. The GLP-1 receptor and GCG receptor co-agonist polypeptide derivative has GLP-1 and GCG dual-receptor agonistic activity, and has prolonged...
|
|
WO/2023/197930A9 |
Provided are a hybrid protein containing a CFH functional unit and a DAF functional unit, an encoding nucleic acid thereof, and a method and use thereof for treating related diseases or disorders of a complement system.
|
|
WO/2024/007978A1 |
A linker peptide, an FVIII protein containing the linker peptide or a variant thereof, and the use thereof, belonging to the field of genetic defect treatment drugs.
|
|
WO/2024/011250A1 |
Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and/or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus...
|
|
WO/2024/009093A1 |
The present invention relates to a cell which expresses a tri-specific chimeric antigen receptor (CAR) with multiple antigen specificities. The cell targets multiple antigens characteristic of acute myeloid leukemia (AML), specifically C...
|
|
WO/2024/008979A1 |
The present disclosure provides chimeric proteins comprising an extracellular domain, a transmembrane domain and a linker between said extracellular domain and said transmembrane domain, cells comprising said chimeric proteins, cell comp...
|
|
WO/2024/008896A1 |
The present invention relates to an engineered unicellular Stramenopile microalga comprising a loss of function of the homologous Seipin gene, an in vitro method of producing triacylglycerols (TAG), and uses thereof.
|
|
WO/2024/002149A1 |
Provided are a recombinant type-III collagen and a method for preparing same and use thereof. The amino acid sequences of the recombinant type-III collagen are set forth in SEQ ID NOs: 1, 2, and 3.
|
|
WO/2024/002269A1 |
Provide are a protein-mediated mRNA targeting molecule, a method for preparing same, and use thereof. The protein-mediated mRNA targeting molecule is formed by connecting an mRNA to a targeting protein group by means of PolyA at a 3' ter...
|
|
WO/2023/180523A9 |
The present disclosure relates to a method for purifying fusion proteins comprising a lipocalin mutein and an antibody or an antigen-binding fragment thereof.
|
|
WO/2024/006842A2 |
The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Bordetella or an immune response relevant to a Bordetella infection including T cells responsive to one or more Bordet...
|
|
WO/2024/006930A2 |
We have generated a 3D model of the glycoprotein B (gB) of Epstein-Barr virus (EBV) to design candidate stabilizing mutations that increase the stability of the prefusion state essential for an effective EBV gB based vaccine. Provided he...
|
|
WO/2024/003346A1 |
The present invention relates to a mammalian non-human cell line, specifically Chinese hamster ovary (CHO) cells, that is genetically modified to express poxvirus host range genes CP77, K1 L and/or SPI-1 which are not expressed in MVA, a...
|
|
WO/2024/005422A1 |
The present invention relates to B7-H6 variants with improved binding affinity for NKp30. The B7-H6 variants of the present invention can increase the activation of natural killer (NK) cells due to significantly increased binding affinit...
|
|
WO/2024/007031A1 |
Cannabinoids are a promising and potent class of agents in the management of pain, and preclinical studies in rodent models suggest that cannabinoids may be particularly potent in relieving neuropathic pain. Despite the potential benefit...
|
|
WO/2024/003353A1 |
The present invention is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytoki...
|
|
WO/2023/215711A9 |
This application relates to compositions and methods comprising epigenetic editors for epigenetic modification of PCSK9, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epig...
|
|
WO/2024/006576A1 |
Disclosed are MHC Class II constructs (CIICs) comprising DQ and DR gene products that can present peptide epitopes associated with cancers, allergies, autoimmune diseases (e.g., T1D and celiac disease), GVHD, HGVD, and infections to T ce...
|
|
WO/2024/000223A1 |
Provided are a modified viral envelope protein and the use thereof, and a pseudotype virus-like particle containing the modified viral envelope protein and the use thereof. The modified viral envelope protein can improve the infection ef...
|
|
WO/2024/006677A1 |
Disclosed herein is a genetically modified rodent animal comprising a humanized Clec9a gene in its genome. Also disclosed herein are an isolated rodent tissue or cell including a rodent embryonic stem cell, a rodent embryo, a method of m...
|
|
WO/2024/004580A1 |
[Problem] To provide: a novel pathological marker useful in testing disease progression toward vasculitis and in testing the risk of COVID-19 becoming severe; and a means, using the marker, of testing disease progression toward vasculiti...
|
|
WO/2024/001484A1 |
Provided is a CCK secretion-promoting peptide QGDVVALPA targeting a calcium sensing receptor. The peptide can be artificially synthesized by adopting a chemical solid-phase synthesis method and can also be obtained after enzymolysis, sep...
|
|
WO/2024/006563A1 |
The present disclosure provided to IL-12 polypeptides with at least one amino acid substitution, pharmaceutical compositions, diagnostic compositions, and kits containing the polypeptides, nucleic acids and expression vectors encoding th...
|
|
WO/2024/002311A1 |
Disclosed herein are methods of enhancing extracellular vesicle production.
|
|
WO/2024/003131A1 |
The present invention relates to an agent that inhibits the expression or activity of the G Protein-Coupled Receptor 182 (GPR182) protein for use in the treatment or prevention of a pathological condition selected from myocardial infarct...
|
|
WO/2024/003400A1 |
The invention relates to a composition, in particular solid, comprising a permeation enhancer, said permeation enhancer being an acylated aminoacid substituted on the amine function, also called AC-aa-NS, said composition comprising in p...
|
|
WO/2024/006734A1 |
The present disclosure relates generally to the field of immunology, and particularly relates to methods useful for preparing major histocompatibility complex (MHC) multimer reagents and methods for using the same for characterization of...
|
|
WO/2024/006792A1 |
This invention relates to compositions and methods for modifying FASCIATED EAR2 (FEA2) genes in plants, optionally to modify meristem size. The invention further relates to plants having increased kernel row number produced using the met...
|
|
WO/2024/003359A1 |
The present invention relates to polypeptides acting as amylin receptor (hAMY3R) agonists with improved chemical stability.
|
|
WO/2024/003890A1 |
The invention provides a peptide having an antimicrobial activity comprising the amino acid sequence as set forth in SPRVCIRVCRNGVCYRRCWG (SEQ ID NO:1), wherein at least one, two, three or all of the cysteine amino acids of the sequence ...
|
|
WO/2024/003118A1 |
The invention is related to a chimeric checkpoint receptor (CCR) fusion protein, a nucleic acid molecule encoding said fusion protein, a vector comprising said nucleic acid molecule, a host cell comprising said nucleic acid molecule and/...
|
|
WO/2024/006791A1 |
This invention relates to compositions and methods for modifying FASCIATED EAR2 (FEA2) genes in plants, optionally to modify meristem size. The invention further relates to plants having increased kernel row number produced using the met...
|
|
WO/2024/003555A1 |
The invention relates to chemokine -binding peptides and combinations thereof, and methods and uses thereof.
|
|
WO/2024/005250A1 |
The present invention relates to an oncolytic virus simultaneously expressing the complement control proteins CD55 and CD59. The oncolytic virus of the present invention maintains efficacy even upon intravenous injection and thus can be ...
|
|
WO/2023/086771A9 |
Capture membranes for lanthanide metal ions can be made from fusion proteins having at least one lanthanide metal binding sequence (SEQ ID NO: 1-4) covalently bound to a silk-elastin- like polymer (SELP). Capture membranes can be made fr...
|
|
WO/2024/006961A1 |
Provided herein are polypeptides comprising a Neo-2/15 mutant, polypeptides comprising a Neo-2/15 mutant and an agent for targeting T-regulatory cells, and methods of their use for treating disease. Related nucleic acids, vectors, host c...
|
|
WO/2024/005499A1 |
The present application relates to a method for producing 2'-fucosyllactose, and provides a method for producing 2'-fucosyllactose, the method comprising: a step for culturing a microorganism having alpha-1,2-fucosyltransferase in a medi...
|
|
WO/2024/003238A1 |
The present invention relates to vaccines based on a viral vector for the delivery of antigens targeting an infectious disease. Specifically, the invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding antigens o...
|
|
WO/2024/000303A1 |
Disclosed are a recombinant binding protein targeting TSLP and the use thereof. The recombinant binding protein comprises at least one ankyrin repeat domain that specifically binds to TSLP, wherein the ankyrin repeat domain comprises thr...
|
|
WO/2024/006855A1 |
The present disclosure is directed to methods of treating muscular dystrophy in a subject in need thereof. In certain aspects, the method comprises administering an AAV vector, e.g., an AAVrh74 vector, and an enzyme that cleaves IgG to t...
|
